ERBB2 and breast cancer: Similarly, it has been demonstrated that the down-regulation of ErbB3 expression, and of its downstream pathways, by the HDACi SNDX-275, is a crucial mechanism to overcome the resistance to the anti-ErbB2 antibody trastuzumab in an ErbB2-overexpressing breast cancer model [47, 48].